Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending May 2013. The report details a specific corporate action regarding share repurchases executed on May 23, 2013, following shareholder authorization at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on share capital movements.
- Shares Purchased: 1,400,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,746.5 pence per share; lowest price paid was 1,735.5 pence per share.
- Treasury Holdings (Settled): 499,901,827 shares (9.21% of total issued share capital).
- Treasury Holdings (Including Unsettled): 501,492,012 shares (10.18% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,927,854,150 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,400,000 shares for treasury. Consequently, the percentage of shares held in treasury increased to 10.18% of total voting rights when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Conduct Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (4,927,854,150) for calculating disclosure thresholds under FCA rules.
- Confirm the updated treasury share count (501,492,012 including unsettled) for voting rights calculations.
- Note that this announcement does not constitute an offer to purchase or subscribe for securities.